About Us

Who We Are

The Johns Hopkins University Baltimore-India Clinical Trials Unit (JHUBI-CTU) is a collaboration and integration of 2 Clinical Research Sites (CRS’s):
 

The CTU supports clinical studies offered by 3 NIAID Clinical Research Networks

  1. AIDS Clinical Trials Group (ACTG)
  2. HIV Prevention Trials Network (HPTN)
  3. International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)

The JHUBI-CTU works with patients at high risk for HIV and Hepatitis C in Baltimore and at one of the largest HIV/infectious diseases clinical care and clinical research units on the Indian subcontinent.

The CTU includes a highly experienced international leadership that is also uniquely positioned to make significant and strategic scientific contributions. 
 

Three Specific Aims

  1. Science. The CTU’s innovative Scientific Coordinating Committees bring together expertise in our strongest fields: Tuberculosis, Hepatitis, HIV Cure, HIV Prevention, Clinical Pharmacology, Pediatric & Adolescent Research, Inflammation & End-Organ Complications, Antibiotic Resistance, and Training & Mentorship.

    The Committees are highly creative in developing new study proposals, identifying and prioritizing studies for site implementation, and encouraging young and international investigators to contribute to novel scientific concepts valued by the networks we support.

  2. Populations. Our sites work with important and often under-represented populations.

    1. Impoverished urban African-Americans and other communities of color, those with a history of intravenous drug use and substance abuse in Baltimore 
    2. Vulnerable sexually active young urban MSM and women in Baltimore 
    3. Pregnant women, adolescents, and adults in urban India.


    Because both sites provide top-quality clinical care and clinical research at the same facility, we can efficiently identify potential research participants and rapidly enroll them into high priority research using our integrated clinical care and clinical research teams.

  3. Management. Our efficient and highly integrated administrative structure facilitates high quality clinical research while taking advantage of shared resources, investigator expertise and synergies among sites.

Clinical Trials

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

A5302:  BioBank for Surrogate Marker Research for TB...

Primary Objective To obtain sputum, serum, urine, and peripheral blood mononuclear cells (PBMCs) for central TB biorepository...

Read More

A5329: Interferon –Free Therapy for Chronic Hepatitis C...

A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...

Read More

NWCS 445: Novel Biomarkers to Shorten TB Treatment

Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...

Read More

P1060:  Phase II, parallel, randomized, clinical trials...

A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been...

Read More